Translate page

Genomics Alliance LogoThe iCMLf Genomics Alliance - Investigating clonal hierarchy in CML

 
The iCMLf/HARMONY Genomics project is analysing genetic data from hundreds of CML patients, aiming to uncover the hierarchy of genomic events in CML. This will enhance our understanding of how genetic variations impact treatment outcomes.

Questions we hope to answer include:

  • Clinical relevance of mutations at diagnosis?
  • Do some mutations confer a poorer prognosis?
  • Can poor risk be overcome with more potent drugs?
  • Will mutations at diagnosis impact the chance of treatment-free remission?

Progress to date:

  • All sites now completed data upload!
  • 9 sites finalised, with upload, transfer and mapping completed
  • 3 sites finalising mapping
  • 1,148 cases available for analysis with approximately 300 still coming.

Remission Alliance RGBThe iCMLf TFR Alliance - Optimising Treatment Free Remission

While a cure for CML remains the ultimate goal, treatment free remission (TFR) is often the treatment target for those on TKI therapy. Still, with only around 50% of attempts resulting in sustained TFR, there is much room for improvement. The iCMLf TFR Alliance is focused on increasing the success rates of TFR, enabling more patients to stop therapy while maintaining remission. The iCMLf/HARMONY TFR Big Data project plans to evaluate over 2,500 cases looking at factors that predict successful, sustained TKI discontinuation, potentially linking it to long-term cure.

Progress to date:

  • 19 sites from 14 countries are participating in the iCMLf/HARMONY TFR project.
  • 8 sites are finalised, with upload, transfer and mapping completed
  • 2 sites are finalising mapping & 6 sites are waiting for mapping to begin
  • 3 sites are preparing their data for transfer
  • 1,198 cases available for analysis with approximately 1,400 still coming
  • Data analysis will begin in Q3 2025

Mount Kilimanjaro has been climbed. CML can be cured.

IMG 20191104 WA0002 Mount Kilimanjaro has been climbed! In 2019 the iCMLf undertook a unique charity challenge to raise funds for the iCMLf CURE CONSORTIUM The funds raised will play an integral role in getting closer to a cure for CML. An amazing team of 26 climbers – researchers, doctors, patients and supporters from all over the world raised over $300,000 for the work of the Foundation. From 26 October to 3 November the Climb for a cure team sucessfully climbed Mount Kilimanjaro. The youngest climber was 18 years old, a CML patient from Germany.

$304,464 total funds raised by the Climb for a Cure team

26 participants from all over the world including Africa, Australia, Europe, Middle East, South America and USA

Click here to see our Climb for a Cure Mount Kilimanjaro video

Timothy HughesThe iCMLf CURE CONSORTIUM

Concerted global effort working towards a cure for CML

"There are currently estimated to be over 800,000 CML patients globally. CML is predicted to become the most prevalent leukaemia by 2040 when there are projected to be over 3 million patients worldwide. A concerted global effort working towards a cure is imperative.
The iCMLf is uniquely positioned to drive this effort.” 
(Tim Hughes, iCMLf Chairman)

With the increasing prevalence of CML a concerted global effort working towards a cure is imperative. As a global organisation led by clinicians and researchers at the forefront of this disease, the iCMLf is uniquely positioned to do this. The iCMLf is increasingly turning to global priorities through precision medicine approaches aiming to improve outcomes for patients with CML.

The iCMLf will drive this effort by bringing interested parties together on specific projects under the banner of 'cure'. The Foundation has formed a CURE CONSORTIUM to focus our efforts working towards a cure for CML. Specifically, we plan to build multicentre global research collaborations to accelerate the development of more effective and safer treatment strategies with the view that these will lead to a cure.

 DSC3214 KopieAlliance 1: The iCMLf Genomics Alliance

Developing a genome-based risk-calculator for newly diagnosed CML patients

The iCMLf has formed a Genomics Alliance to develop a genome-based risk calculator for newly diagnosed CML patients. The Alliance aims to harness the wealth of genomic information that is generated in local CML research projects by building a platform to facilitate data assimilation and sample exchanges. Combining many data sets and facilitating global collaborative studies will enable us to develop a baseline predictor of adverse outcomes.

 DSC3463 KopieAlliance 2: The iCMLf TFR Alliance

Maximising achievement of TFR while minimising failed TFR attempts and other negative outcomes

The iCMLf also formed a second Alliance under the banner of CURE - the iCMLf Treatment-Free-Remission (TFR) Alliance. The mission of the iCMLf TFR Alliance is to maximise achievement of TFR while minimising failed TFR attempts and other negative outcomes.

Six month updateSocials 2

After six months, as we reflect on the journey we embarked on together last November during the iCMLf Climb for a Cure: Annapurna, we're still filled with gratitude for your unwavering support and donations of over $200,000!

Nicola Evans, iCMLf Chief Executive, said, "We are so grateful for the support we received from all over the world. Every day was a tough challenge, but we really felt the support of the iCMLf community along the way. Your support is the backbone of our mission to make a difference in the lives of people with CML."

Read on to find out what we've been up to since the Climb.


The Climb for a Cure Corporate sponsors

Just like on the mountain we would not have been so successful without a strong team. We are very grateful for all the support we received in the past year – from all our climbers who worked so hard to raise funds and to prepare for the climb and from every single person who supported us with their donations - among them an anonymous donation of $ 100,000.

We acknowledge all of our corporate sponsors for their generous support: